IPF Trial Failure Shakes Syndax, Stock Drops 17% While Analysts Stay BullishS&P 500’s modest 0.1 % decline amid a flurry of bank earnings reports.SYNDAX PHARMACEUTICALS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 13/10/2026, 22:03 3 minutes to read
